

























































First Ring-Expanded Maytansin Lactone Accessed by a New
Mutasynthetic Variant
Friederike Wesemann+,[a] Anja Heutling+,[a] Paul Wienecke,[a] and Andreas Kirschning*[a]
A multiblocked mutant strain (ΔAHBA and Δasm12, asm21) of
Actinosynnema pretiosum, the producer of the highly toxic
maytansinoid ansamitocin, has been used for the mutasynthetic
production of new proansamitocin derivatives. The use of
mutant strains that are blocked in the biosynthesis of an early
building block as well as in the expression of two tailoring
enzymes broadens the scope of chemo-biosynthetic access to
new maytansinoids. Remarkably, a ring-expanded macrolactone
derived from ansamitocin was created for the first time.
A promising strategy for creating natural product libraries is to
combine biotechnologically oriented synthetic biology[1] with
synthetic chemistry.[2] The former allows complex molecular
architectures to be created through multistep biosynthesis while
the latter provides large synthetic flexibility for introducing
unnatural but pharmacologically important functions and func-
tional groups.
Sensibly, chemo-biosynthetic strategies can be categorized by
dissecting a synthesis into chemo- and biosynthetic elements
(Figure 1). Semisynthesis is an example for a BIO-CHEM strategy
(case A1) in which first a natural product is formed naturally
followed by chemical derivatization.[2b] If the biosynthesis is
blocked at a late stage the organism can provide advanced
biosynthetic intermediates derived from important secondary
metabolites (Figure 1, case A2).[2c]
An example for the reversed CHEM-BIO scenario (case B) is
mutational biosynthesis (short “mutasynthesis“) in which for
example a mutant strain of a producer organism is blocked in the
formation of an early biosynthetic pathway intermediate.[3]
Administration of so called mutasynthons that are commonly
prepared by chemical synthesis – these are structural analogs of
biosynthetic intermediates – to the mutant strain then results in
new metabolites sometimes referred to as mutaproducts (Figure 1,
case B1). So far, no reports have appeared that utilize mutant
producer strains that are blocked both at an early as well as at a
late stage of the biosynthesis (Figure 1, case B2).
Following the concept B2, we disclose the creation and
mutasynthetic exploitation of a mutant strain of Actinosynnema
pretiosum, the producing strain of the highly cytotoxic polyketide
ansamitocins P-3 (3), a maytansinoid.[4] Only in 2013 it was
approved by the FDA as an antibody drug conjugate against
HER2-positive breast cancer.[5] The strain is genetically blocked in
the formation of 3-amino-5-hydroxybenzoic acid (AHBA, 1) as well
as in two tailoring steps, namely the chlorination (Asm12) and the
amidination (Asm21) leading to almost complete loss of post-PKS
enzyme activity (Scheme 1).[6]
As a consequence, new proansamitocin derivatives can be
obtained that can principally be further modified semisynthetically
thereby further expanding the opportunities to generate new
nature-derived macrolactams.
Over the past years[7] we mostly employed ΔAHBA mutant
strains (resembling case B1). AHBA 1[8] is formed from UDP-glucose
through a unique variation of the shikimate acid pathway
(Scheme 1).[9] Processing through seven PKS modules furnishes
seco-proansamitocin that undergoes macrolactamization by an
amide synthase that is not part of the PKS to yield proansamitocin
(2).[10,11] Finally, six tailoring steps provide ansamitocin P-3 (3).[10]
Commonly, the protocols can be conducted with unmodified
benzoic acids, because activation to the corresponding SCoA
esters occurs before the in vivo uploading onto the PKS.[12]
The new mutant strain (AH1) was constructed according to
the procedure of Yu et al.[10] The plasmid pHGF9029 was delivered
into A. pretiosum Δasm12/21[6] by conjugation with Escherichia coli.
Positive clones where detected by feeding experiments with and
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Figure 1. Selected concepts of chemo-biosynthetic strategies (blue: chemical
synthesis, orange: biosynthesis, dark blue: final product, green: position of
block; semisynthesis=BIO-CHEM and three concepts of mutasynthesis=
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without AHBA 1. Fermentation conditions were adapted to those
previously described for the ΔAHBA mutant strain (HGF073) of A.
pretiosum.[7a] The monitoring of proansamitocin titers during
fermentation revealed that highest concentrations are observed
on day ten post inoculation (p.i.). For ansamitocin production[13]
the addition of the amino acid L-valine was beneficial. Unexpect-
edly, also in the present case increased proansamitocin production
was observed upon supplementation of L-valine. In fact, L-valine is
a biosynthetic precursor for the ester side chain at C3 and this
transfer does not occur in strain AH1. We also found that pulse
feeding of 2.5 g/L fructose on days 3, 4 and 5 p.i. led to
significantly increased proansamitocin (2) titers (Figure S2 in the
Supporting Information) which was also reported for ansamitocin
P-3 (3) titers produced by the wild-type strain.[14]
Upon feeding of AHBA 1 to strain AH1 proansamitocin (2) and
several derivatives 2, 4–11 were isolated after extensive HPLC. As
expected, proansamitocin (2) was the main product formed
(Figure 2). Macrolactams 4–6 were disclosed before when using a
Δasm12/21 mutant strain of A. pretiosum.[15] 19-Hydroxy proansa-
mitocin (7), 10-desmethoxy proansamitocin (8) and macrolactams
9–11 that mainly differ in the stereochemistry and location around
the diene moiety (C10–C14) are new members of the proansami-
tocin family. The structure elucidation relied on NMR spectroscopic
analyses that included the determination of nuclear Overhauser
effects (nOe; Figure 3).
Having established the ability of the new multiblocked mutant
strain AH1 to accept and process AHBA 1, we next administered
different aromatic acids 12–31 to a growing culture of strain AH1
(scale 3 x 50 mL). The formation and presence of new
proansamitocin derivatives was determined by UPLC-HRMS/MS
analyses after extraction with ethyl acetate.
Halogenated 3-aminobenzoic acids 12–16 were processed by
strain AH1 to the corresponding macrolactams (Figure 4). Mass
Scheme 1. Overview of ansamitocin 3 biosynthesis via proansamitocin (2),
genes of tailoring enzymes and genes blocked in new strain AH1 of
Actinosynnema pretiosum; (green: position of blocks in this work).[6,10]
Figure 2. Proansamitocin (2) and (oxygenated) derivatives 4–11 produced by
A. pretiosum (strain AH1) after supplementation of AHBA 1. [a] Stereo-
chemistry at C10 not assigned.
Figure 3. Coupling constants of 10-H in (10R)-2 and (10S)-proansamitocin 4,
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spectrometric analyses of the crude extracts obtained after feeding
of 3-amino-(het)arenecarboxylic acids 17–22 revealed no accept-
ance and processing to the corresponding proansamtocin deriva-
tives.
A second series of benzoic acids that are not anilines but
rather 3-aminomethyl- (23) and 3-hydroxymethylbenzoic acids (24,
25 and 27–31) as well as phenylacetic acid derivative 26. HRMS
analysis of crude extracts obtained from feeding experiments
conducted with 24 and 25 revealed the presence of macrocyclic
products while the corresponding seco-acid was the result from
mutasynthetic processing of 23.
Surprisingly, feeding experiments with phenylacetic acid 26
revealed formation of proansamitocin (2). One possible explan-
ation could be the oxidation of 26 to the corresponding 2-oxo
derivative which is followed by oxidative decarboxylation (like
pyruvate!acetyl-CoA) to AHBA 1 being activated as CoA
thioester. The other carboxylic acids 27–31 did not act as
processible mutasynthons in this study.
With these results in hand we carried out large-scale
fermentations (up to 3.6 L) choosing the most promising benzoic
acids 12, 14–16 and 25. The selection was based on semi-
quantitative analysis of signal intensities in the UPLC chromato-
grams (for details see the Supporting Information). Consequently,
we did not include aminobenzoic acids 13 as well as aminobenzyl
23 and hydroxymethylbenzoic acids 24 for large-scale fermenta-
tions despite the fact that test fermentations revealed PKS
processing.
As a result we isolated new proansamitocin derivatives 32–38
after purification by column chromatography (SiO2), size exclusion
chromatography (LH-20) and preparative HPLC (C18 and CN
columns). Most remarkably, supplementation of 3-hydroxy-5-
(hydroxymethyl)benzoic acid (25) to a growing culture of strain
AH1 yielded three products that resulted from complete PKS-
processing. Besides the seco-acid 38, the two epimeric, ring-
expanded macrolactones 37a and 37b, were collected (Figure 5).
Support for their formation was gained when comparing the
chemical shift (δ) of the benzylic methylene protons of benzyl
alcohols 25 and 38 with the epimeric macrolactones 37 a,b
[ArCH2O-: 25 ([D6]DMSO) δ=4.46 (s, 2H) ppm; 37a and 37b ([D6]
benzene) δ=5.05 (d, J=13.0 Hz, 1H) and 4.97/4.92 (d, J=13.0 Hz,
Figure 4. Aromatic acids 12–31 tested as mutasynthons for strain AH1. First
MS data (m+Na+) of expected proansamtocin derivatives collected from
crude products are given. [a] No PKS-processed products detected; [b]
detoxification products (benzamides) or starting benzoic acids detected; [c]
processing occurred but only seco-acids detected. Test fermentations were
carried out in three parallel experiments accompanied by two positive
controls (with AHBA addition) and one negative control (without addition of
mutasynthon).
Figure 5. Fermentations using mutasynthons 12, 14–16 and 25 as well as
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1H); 38 δ=4.50 (s, 2H) ppm]. These downfield shifts are diagnostic
for O-acylated secondary alcohols as found in macrolactones
37a,b. It has to be noted that proansamitocins are prone to
epimerization at C10, evident from the isolation of proansamito-
cins 2 and 4 that we have never noted for fully processed
ansamitocin P3 (3).[7]
The two 10-epimers 37a,b were identified by comparison of
the coupling constants J10,11 and J10,12 with those found in epimeric
proanamsitocins 2 and 4 (Figure 3 for major 10R isomer 37a:
J10,11=7.0 Hz and J10,12=0.9 Hz; for minor 10S isomer 37b: J10,11 =
5.3 Hz and J10,12=1.7 Hz). It has to be stressed that this is the first
example of an ansamitocin derivative ever reported that bears an
expanded ring system and a lactone instead of a lactam
substructure.
The monitoring of the mutasynthetic experiment that leads to
macrolactones 37a,b revealed that seco-acid 38 is not the
precursor of the macrolactones or a side product of macro-
cyclization but rather its hydrolysis product (Figure 6). Over a
period of 12 days the titers for macrolactones 37 first increased to
about 5 mg/L before it a dramatically decreased until it could not
be detected anymore. During that time, the formation of seco-acid
38 continuously increased to a value of about 4 mg/L. It must be
noted that formation of the corresponding macrolactones using A.
pretiosum (ΔAHBA, strain HGF073) was not found in previous
experiments.[16]
In summary, expanding the concept of mutasynthesis by
designing multiblocked mutant strains of Actinosynnema pretiosum
opens the door to access new derivatives of biosynthetically
advanced macrocyclic PKS intermediates. For the first time a ring
expanded 20-membered ansamitocin macrolactone could be
generated, revealing an unusual promiscuity and chemoselectivity
of the amide synthase asm9 that commonly catalyzes macro-
lactam formation. These results suggest that this amide synthase
may become a chemical tool of interest for performing
macrocylizations.[11]
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Figure 6. Monitoring the formation of macrolactone 37 (*) and seco-acid 38
(○) by AH1 over a period of 12 days (feeding of 1.65 mmol/L on days 3, 4
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